Home > News content

The US FDA warned that a new crown vaccine deposited high risk of heart disease: its stock price plummeted by more than 20%

via:凤凰网     time:2022/6/5 8:01:44     readed:110

The United States Food and Drug Administration (FDA) reported on Friday local time that there was a risk of heart inflammation after the new crown vaccine of Novavax. Although the company's data shows that its vaccine can improve people's ability to resist the new crown virus.

FDA warned,The risk of inoculation of Norwavax's new crown vaccine is higher than other vaccines. On Friday, Novawax was sold by investors, and its stock price fell more than 20%.

Novawax's stock price fell 86%compared with the record in February 2021, and its performance was far inferior to other vaccine manufacturers. Moderna fell about 26%at the same time because the new crown vaccine market was fiercely competitive and market demand was declining.

From December 27, 2020 to September 27, 2021, Novawax tested nearly 30,000 participants. Studies have found that the effectiveness of its new crown vaccine to adults is 90.4%.However, within more than 20 days after vaccination, 5 patients with myocarditis and pericarditis were reported.

These data were released before the FDA meeting on June 7th. The meeting will decide whether to approve Novawax's new crown vaccine for emergency use authorization.

FDA said that Norwavacis has been required to mark myocarditis and pericarditis as the "important recognition risk" of its new crown vaccine. But Novawax has not agreed to such a practice.

美FDA警告一新冠疫苗存患心脏病高风险:其股价大跌逾20%

Novawax issued a statement saying that in part of the study, the cases of myocarditis found were within the expected range, and we believe that there is no sufficient evidence to establish causality.

FDA researchers wrote: "The existing data of short -term follow -up shows that the symptoms of most people have been resolved, and there is no information about the potential long -term sequelae." FDA pointed out that a patient in the placebo group was during the study period. There are also myocarditis.

FDA added: "According to the efficacy of the clinical trial of the vaccine,Due to the spread of Omikon, this vaccine is more likely to provide some meaningful protection for new crown infections, especially for more serious diseases. "

Novawax's vaccine does not use MRNA technology. It is based on recombinant protein, just like creating influenza vaccines. Therefore, it is easier to transport and manage to help increase the vaccination rate.

美FDA警告一新冠疫苗存患心脏病高风险:其股价大跌逾20%

translate engine: Google

China IT News APP

Download China IT News APP

Please rate this news

The average score will be displayed after you score.

Post comment

Do not see clearly? Click for a new code.

User comments